LABCORP HOLDINGS INC. 8-K

What Happened Labcorp Holdings Inc. filed an 8-K on May 26, 2026 reporting final, certified results from its 2026 Annual Meeting of Shareholders. As of the March 26, 2026 record date, 82,187,046 shares were outstanding and 76,382,627 shares were represented at the meeting (quorum). All board nominees listed in the proxy were elected to serve until the 2027 annual meeting; notable vote totals show Dr. Garheng Kong received substantial opposition. Shareholders also approved the advisory "say-on-pay" vote and ratified Deloitte & Touche LLP as the company’s independent auditor for 2026.

Key Details

• Shares outstanding (record date): 82,187,046; shares present/in person or by proxy: 76,382,627.
• Directors elected (term to 2027): Adam H. Schechter; Kerrii B. Anderson; Victor Bulto; Jeffrey A. Davis; Kirsten M. Kliphouse; Garheng Kong, M.D., Ph.D.; Peter M. Neupert; Richelle P. Parham; Paul B. Rothman, M.D.; John H. Sampson, M.D., Ph.D.; Kathryn E. Wengel.
• Highest dissent: Garheng Kong — For: 50,153,535; Against: 20,110,931; Abstentions: 294,749 (broker non‑votes: 5,823,412).
• Say-on-pay (advisory) vote: For 66,519,291; Against 3,735,777; Abstain 304,147 (broker non‑votes: 5,823,412).
• Auditor ratification: Deloitte & Touche LLP ratified — For 76,291,589; Against 53,650; Abstain 37,388.

Why It Matters These certified vote results confirm the company’s board composition and governance direction for the coming year, including a notable level of shareholder opposition to one director (Dr. Kong). The approval of the advisory executive compensation proposal signals broad shareholder support for the company’s pay practices, while ratifying Deloitte maintains continuity in external audit oversight. Investors should note the voting levels and any director opposition as part of their assessment of governance and shareholder sentiment.